Jing Li

发表

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.

Manuel Hidalgo, Ming Zhao, Mats O Karlsson, 2006, Journal of the National Cancer Institute.

CYP 3 A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

M. Hidalgo, M. Karlsson, S. Baker, 2022 .

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

A. Jimeno, M. Hidalgo, R. Donehower, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes

M. Hidalgo, S. Baker, Ming Zhao, 2007, Clinical Cancer Research.

Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.

A. Jimeno, M. Hidalgo, S. Baker, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

M. Hidalgo, M. Moore, S. Baker, 2006, Clinical Cancer Research.

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

M. Hidalgo, S. Baker, W. Messersmith, 2006, Investigational New Drugs.

362 Binding of gefitinib (ZD1839) to human plasma proteins: in vitro and clinical pharmacokinetic (PK) studies

M. Hidalgo, S. Baker, W. Messersmith, 2004 .

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

J. Nortier, H. Guchelaar, M. Karlsson, 2007, Clinical Cancer Research.

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

Jing Li, Manuel Hidalgo, Alex Sparreboom, 2007, Cancer biology & therapy.

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

M. Hidalgo, J. Verweij, R. Ingersoll, 2006, Journal of the National Cancer Institute.

Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia

J. Verweij, W. Graveland, S. Baker, 2005, Clinical pharmacology and therapeutics.

Molecular mechanisms of interethnic differences in irinotecan disposition: Impact of variants in ABCG2

J. Verweij, E. Tan, S. Baker, 2005 .

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.

A. Jimeno, M. Hidalgo, R. Donehower, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients

S. Baker, B. Baguley, R. Pili, 2008, Clinical Cancer Research.

Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-DisruptingAgent 5,6-Dimethylxanthenone-4-Acetic Acid inCancer Patients

S. Baker, B. Baguley, R. Pili, 2008 .

Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

J. Nortier, Jing Li, N. P. Erp, 2022 .

Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients

M. Hidalgo, M. Karlsson, S. Baker, 2005 .